Talia C. Oughourlian

Talia C. Oughourlian

Auto-generated profile, based on publicly available information

Talia C. Oughourlian

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2021 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
AHAkifumi Hagiwara
Akifumi Hagiwara
MBMark Bydder
Mark Bydder
TOT.C. Oughourlian
T.C. Oughourlian
JYJingwen Yao
Jingwen Yao
NSNoriko salamon
Noriko salamon
BEBenjamin M. Ellingson
Benjamin M. Ellingson
SUMMARY: Sodium MR imaging has the potential to complement routine proton MR imaging examinations with the goal of improving diagnosis, disease characterization, and clinical monitoring in neurologic diseases. In the past, the utility and exploration of sodium MR imaging as a valuable clinical tool have been limited due to the extremely low MR signal, but with recent improvements in imaging techniques and hardware, sodium MR imaging is on the verge of becoming clinically realistic for conditions that include brain tumors, ischemic stroke, and epilepsy. In this review, we briefly describe the fundamental physics of sodium MR imaging tailored to the neuroradiologist, focusing on the basics necessary to understand factors that play into making sodium MR imaging feasible for clinical settings and describing current controversies in the field. We will also discuss the current state of the field and the potential future clinical uses of sodium MR imaging in the diagnosis, phenotyping, and therapeutic monitoring in neurologic diseases.

4 August 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BEBenjamin M. Ellingson
Benjamin M. Ellingson
AHAkifumi Hagiwara
Akifumi Hagiwara
CMConnor J. Morris
Connor J. Morris
NCNicholas S Cho
Nicholas S Cho
SOSonoko Oshima
Sonoko Oshima
TCTimothy F Cloughesy
Timothy F Cloughesy
Purpose: Antiangiogenic therapies are known to cause high radiographic response rates due to reduction in vascular permeability resulting in a lower degree of contrast extravasation. In this study, we investigate the prognostic ability for model-derived parameters describing enhancing tumor volumetric dynamics to predict survival in recurrent glioblastoma treated with antiangiogenic therapy. Experimental Design: N = 276 patients in two phase II trials were used as training data, including bevacizumab ± irinotecan (NCT00345163) and cabozantinib (NCT00704288), and N = 74 patients in the bevacizumab arm of a phase III trial (NCT02511405) were used for validation. Enhancing volumes were estimated using T1 subtraction maps, and a biexponential model was used to estimate regrowth (g) and regression (d) rates, time to tumor regrowth (TTG), and the depth of response (DpR). Response characteristics were compared to diffusion MR phenotypes previously shown to predict survival. Results: Optimized thresholds occurred at g = 0.07 months−1 (phase II: HR = 0.2579, P = 5 × 10−20; phase III: HR = 0.2197, P = 5 × 10−5); d = 0.11 months−1 (HR = 0.3365, P < 0.0001; HR = 0.3675, P = 0.0113); TTG = 3.8 months (HR = 0.2702, P = 6 × 10−17; HR = 0.2061, P = 2 × 10−5); and DpR = 11.3% (HR = 0.6326, P = 0.0028; HR = 0.4785, P = 0.0206). Multivariable Cox regression controlling for age and baseline tumor volume confirmed these factors as significant predictors of survival. Patients with a favorable pretreatment diffusion MRI phenotype had a significantly longer TTG and slower regrowth. Conclusions: Recurrent glioblastoma patients with a large, durable radiographic response to antiangiogenic agents have significantly longer survival. This information is useful for interpreting activity of antiangiogenic agents in recurrent glioblastoma.

14 September 2020 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
HTHiroyuki Tatekawa
Hiroyuki Tatekawa
AHAkifumi Hagiwara
Akifumi Hagiwara
HUHiroyuki Uetani
Hiroyuki Uetani
JYJingwen Yao
Jingwen Yao
TOTalia C. Oughourlian
Talia C. Oughourlian
BEBenjamin M. Ellingson
Benjamin M. Ellingson

11 March 2021 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
HTHiroyuki Tatekawa
Hiroyuki Tatekawa
HUHiroyuki Uetani
Hiroyuki Uetani
AHAkifumi Hagiwara
Akifumi Hagiwara
JYJingwen Yao
Jingwen Yao
TOTalia C. Oughourlian
Talia C. Oughourlian
BEBenjamin M. Ellingson
Benjamin M. Ellingson

10 July 2026 in Radiotherapy and Oncology
Verified
Journal Article
Open access
NNNiki Nourmohammadi
Niki Nourmohammadi
CKCamellia Kashani
Camellia Kashani
TOTalia Oughourlian
Talia Oughourlian
JNJohn Nikitas
John Nikitas
JDJie Deng
Jie Deng
DMDrew Moghanaki
Drew Moghanaki
Assessments of local control (LC) following stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) play a crucial role in evaluating treatment efficacy. However, there is significant variability in how LC is defined and assessed across studies, making it challenging to compare outcomes and establish standardized benchmarks. This heterogeneity impacts clinical decision-making, prognostic assessments, and interpretations of lung SBRT efficacy in both research and clinical practice. A systematic review was conducted following PRISMA guidelines to identify criteria used in reporting post-SBRT local control (LC) rates. A comprehensive PubMed search identified studies published between 2006 and 2023 reporting LC or primary tumor control (PTC) rates following SBRT for early-stage NSCLC. Eligible studies were independently reviewed, and LC definitions were categorized based on the anatomical sites considered and the criteria used to define treatment site progression. Of 155 studies identified, 113 met the inclusion criteria. LC determinations were described as 'local control', 'local failure', 'local recurrence', or 'primary tumor control' in 39%, 32%, 24%, and 4% of studies, respectively. Anatomic sites assessed for LC included recurrence events outside of the primary tumor site in 32% of studies. These LC assessments included progression within the same lobe, ipsilateral lung, and regional nodes in 68%, 11%, 4%, and 2% of studies, respectively; 15% did not specify the anatomical location(s) evaluated. Articles published after 2021 were more restrictive and limited LC evaluations to PTC in 95.7%. Regarding PTC evaluations, 12 different criteria were used ranging from reporting the specific imaging modality used (CT or PET), growth threshold assessed by Response Evaluation Criteria in Solid Tumors (RECIST) or up to 50% increase in diameter, minimum growth duration (2-36 months or serial changes), or histopathological confirmation in 28%, 31%, 18%, and 1%, respectively. LC evaluations following lung SBRT have evolved away from considering progression events in the same lobe and regional lymph nodes. Studies reporting PTC rates often do not state the assessment methods used and utilize non-objective criteria that may not be reproducible. Future studies reporting post-SBRT LC rates should clearly state the anatomic sites considered, document the objective measures used for PTC assessments, and report the minimum duration of post-treatment surveillance to better inform future research aiming to improve post-SBRT monitoring strategies.

13 October 2023
Verified
Other
Open access
BEBenjamin M. Ellingson
Benjamin M. Ellingson
AHAkifumi Hagiwara
Akifumi Hagiwara
CMConnor J. Morris
Connor J. Morris
NCNicholas S Cho
Nicholas S Cho
SOSonoko Oshima
Sonoko Oshima
TCTimothy F Cloughesy
Timothy F Cloughesy
Purpose:Antiangiogenic therapies are known to cause high radiographic response rates due to reduction in vascular permeability resulting in a lower degree of contrast extravasation. In this study, we investigate the prognostic ability for model-derived parameters describing enhancing tumor volumetric dynamics to predict survival in recurrent glioblastoma treated with antiangiogenic therapy.Experimental Design:N = 276 patients in two phase II trials were used as training data, including bevacizumab ± irinotecan (NCT00345163) and cabozantinib (NCT00704288), and N = 74 patients in the bevacizumab arm of a phase III trial (NCT02511405) were used for validation. Enhancing volumes were estimated using T1 subtraction maps, and a biexponential model was used to estimate regrowth (g) and regression (d) rates, time to tumor regrowth (TTG), and the depth of response (DpR). Response characteristics were compared to diffusion MR phenotypes previously shown to predict survival.Results:Optimized thresholds occurred at g = 0.07 months−1 (phase II: HR = 0.2579, P = 5 × 10−20; phase III: HR = 0.2197, P = 5 × 10−5); d = 0.11 months−1 (HR = 0.3365, P < 0.0001; HR = 0.3675, P = 0.0113); TTG = 3.8 months (HR = 0.2702, P = 6 × 10−17; HR = 0.2061, P = 2 × 10−5); and DpR = 11.3% (HR = 0.6326, P = 0.0028; HR = 0.4785, P = 0.0206). Multivariable Cox regression controlling for age and baseline tumor volume confirmed these factors as significant predictors of survival. Patients with a favorable pretreatment diffusion MRI phenotype had a significantly longer TTG and slower regrowth.Conclusions:Recurrent glioblastoma patients with a large, durable radiographic response to antiangiogenic agents have significantly longer survival. This information is useful for interpreting activity of antiangiogenic agents in recurrent glioblastoma.